NO20052267L - Forbindelser, Preparater og Metoder - Google Patents

Forbindelser, Preparater og Metoder

Info

Publication number: NO20052267L
Authority: NO; Norway
Prior art keywords: preparations; compounds; methods; ksp; triazol
Prior art date: 2002-10-11

Application number

NO20052267A

Other languages

English (en)

Norwegian (no)

Inventor

Jr David John C Morgans

Dashyant Dhanak

Gustave Bergnes

Steven David Knight

Xianping Qian

Original Assignee

Cytokinetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-11

Filing date

2005-05-10

Publication date

2005-05-31

2005-05-10 Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc

2005-05-31 Publication of NO20052267L publication Critical patent/NO20052267L/no

Links

150000001875 compounds Chemical class 0.000 title 1
238000000034 method Methods 0.000 title 1
238000002360 preparation method Methods 0.000 title 1
MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical class O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 abstract 1
230000001413 cellular effect Effects 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20052267A 2002-10-11 2005-05-10 Forbindelser, Preparater og Metoder NO20052267L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41788902P	2002-10-11	2002-10-11
PCT/US2003/031413 WO2004032840A2 (en)	2002-10-11	2003-10-02	Compounds, compositions, and methods

Publications (1)

Publication Number	Publication Date
NO20052267L true NO20052267L (no)	2005-05-31

Family

ID=32094113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052267A NO20052267L (no)	2002-10-11	2005-05-10	Forbindelser, Preparater og Metoder

Country Status (19)

Country	Link
US (1)	US7476743B2 (is)
EP (1)	EP1558588A4 (is)
JP (1)	JP2006502219A (is)
KR (1)	KR20050075356A (is)
CN (1)	CN1726198A (is)
AR (1)	AR044193A1 (is)
AU (1)	AU2003282665A1 (is)
BR (1)	BR0315247A (is)
CA (1)	CA2501938A1 (is)
IL (1)	IL167936A0 (is)
IS (1)	IS7798A (is)
MX (1)	MXPA05003830A (is)
NO (1)	NO20052267L (is)
NZ (1)	NZ539643A (is)
PL (1)	PL375889A1 (is)
RU (1)	RU2005114491A (is)
TW (1)	TW200418818A (is)
WO (1)	WO2004032840A2 (is)
ZA (1)	ZA200503733B (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MXPA06014909A (es) *	2004-06-18	2007-02-28	Chiron Corp	Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
CN101027309B (zh)	2004-08-18	2010-10-27	阿斯利康(瑞典)有限公司	所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
DE102006023337A1 (de) *	2006-05-18	2007-11-22	Merck Patent Gmbh	Triazolderivate II
JP5343363B2 (ja) *	2008-01-31	2013-11-13	アイシン精機株式会社	シートクッション調整装置
CN101643451B (zh) *	2008-08-07	2013-03-06	浙江海正药业股份有限公司	过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
EP2558450A1 (en)	2010-04-15	2013-02-20	Novartis AG	Triazole compounds as ksp inhibitors
WO2012095691A1 (en) *	2011-01-15	2012-07-19	Jubilant Life Sciences Ltd.	An improved process for producing aminopyridines
WO2013134562A1 (en)	2012-03-09	2013-09-12	Inception 2, Inc.	Triazolone compounds and uses thereof
MX376108B (es)	2012-12-20	2025-03-07	Tempest Therapeutics Inc	Compuestos de triazolona y usos de los mismos.
AU2014315151A1 (en)	2013-09-06	2016-03-03	Inception 2, Inc.	Triazolone compounds and uses thereof
SG11201710639YA (en) *	2015-06-22	2018-01-30	Bayer Pharma AG	Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
TW201722958A (zh) *	2015-09-15	2017-07-01	葛蘭素史克智慧財產（第二）有限公司	化學化合物
AU2017380871C1 (en)	2016-12-21	2025-05-15	Bayer Aktiengesellschaft	Antibody drug conjugates (ADCs) having enzymatically cleavable groups
WO2023192499A1 (en) *	2022-03-30	2023-10-05	Primefour Therapeutics, Inc.	Nucleosides for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE793532A (fr) *	1971-12-29	1973-06-29	Upjohn Co	Nouvelles 1,2,4-triazol-3-ones et leur preparation
US3748339A (en)	1972-05-05	1973-07-24	Upjohn Co	2-(3-(1-(dimethylamino)alkyl)-1,5-dihydro-5-oxo - 1 - substituted-4h-1,2,4-triazol-4-yl)benzophenone and process
NO773853L (no)	1976-11-17	1978-05-19	Montedison Spa	Nye fosforsyreestre avledet fra 1,2,4-triazol med insekticid, nematocid og acaricid virkning, og fremstilling av disse
IT1068010B (it) *	1976-11-17	1985-03-21	Montedison Spa	Nuovi esteri fosforici derivati dall' 1-2-4 triazolo ad azione insetticida,nematocida e acaricida e loro preparazione
US4487773A (en)	1981-03-16	1984-12-11	Mead Johnson & Company	1,2,4-Triazol-3-one antidepressants
US5250558A (en) *	1992-01-28	1993-10-05	Merck & Co., Inc.	Substituted triazolinones, triazolinethiones, and triazolinimines as neurotensin antagonists used to treat psychosis
GB9211193D0 (en) *	1992-05-27	1992-07-08	Merck Sharp & Dohme	Therapeutic agents
CA2099233A1 (en) *	1992-06-29	1993-12-30	Conrad P. Dorn	Morpholine and thiomorpholine tachykinin receptor antagonists
WO1997014671A1 (en) *	1995-10-18	1997-04-24	Merck & Co., Inc.	Cyclopentyl tachykinin receptor antagonists
JP2002234874A (ja) *	2000-09-26	2002-08-23	Tanabe Seiyaku Co Ltd	５−フェニルベンジルアミン誘導体、その製法及びその合成中間体
US6727244B2 (en) *	2000-10-26	2004-04-27	Merck & Co., Inc.	Mammalian metabolites of a tachykinin receptor antagonist
IL165624A0 (en) *	2002-06-14	2006-01-15	Merck & Co Inc	Mitotic kinesin inhibitors

2003
- 2003-10-02 NZ NZ539643A patent/NZ539643A/en unknown
- 2003-10-02 CA CA002501938A patent/CA2501938A1/en not_active Abandoned
- 2003-10-02 PL PL03375889A patent/PL375889A1/xx unknown
- 2003-10-02 MX MXPA05003830A patent/MXPA05003830A/es unknown
- 2003-10-02 CN CNA200380105737XA patent/CN1726198A/zh active Pending
- 2003-10-02 US US10/529,634 patent/US7476743B2/en not_active Expired - Fee Related
- 2003-10-02 JP JP2004543136A patent/JP2006502219A/ja active Pending
- 2003-10-02 WO PCT/US2003/031413 patent/WO2004032840A2/en not_active Ceased
- 2003-10-02 AU AU2003282665A patent/AU2003282665A1/en not_active Abandoned
- 2003-10-02 KR KR1020057006260A patent/KR20050075356A/ko not_active Withdrawn
- 2003-10-02 BR BR0315247-2A patent/BR0315247A/pt not_active IP Right Cessation
- 2003-10-02 RU RU2005114491/04A patent/RU2005114491A/ru not_active Application Discontinuation
- 2003-10-02 EP EP03774548A patent/EP1558588A4/en not_active Withdrawn
- 2003-10-09 AR ARP030103684A patent/AR044193A1/es unknown
- 2003-10-09 TW TW092128029A patent/TW200418818A/zh unknown
2005
- 2005-04-10 IL IL167936A patent/IL167936A0/en unknown
- 2005-04-11 IS IS7798A patent/IS7798A/is unknown
- 2005-05-10 NO NO20052267A patent/NO20052267L/no not_active Application Discontinuation
- 2005-05-10 ZA ZA200503733A patent/ZA200503733B/en unknown

Also Published As

Publication number	Publication date
IL167936A0 (en)	2009-02-11
NZ539643A (en)	2006-11-30
PL375889A1 (en)	2005-12-12
WO2004032840A2 (en)	2004-04-22
CA2501938A1 (en)	2004-04-22
US7476743B2 (en)	2009-01-13
EP1558588A2 (en)	2005-08-03
JP2006502219A (ja)	2006-01-19
RU2005114491A (ru)	2006-02-10
TW200418818A (en)	2004-10-01
AR044193A1 (es)	2005-09-07
BR0315247A (pt)	2005-08-30
ZA200503733B (en)	2006-02-22
WO2004032840A3 (en)	2004-10-14
US20060189671A1 (en)	2006-08-24
CN1726198A (zh)	2006-01-25
MXPA05003830A (es)	2005-06-23
EP1558588A4 (en)	2006-11-02
IS7798A (is)	2005-04-11
AU2003282665A1 (en)	2004-05-04
KR20050075356A (ko)	2005-07-20

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20045043L (no)	2005-02-08	Pyrimidinonforbindelser, sammensetninger og fremgangsmater
WO2004018058A3 (en)	2004-07-01	Compounds, compositions, and methods
MY140169A (en)	2009-11-30	Compounds, compositions, and methods
WO2004009036A3 (en)	2004-08-19	Compounds compositions and methods
WO2004034972A3 (en)	2004-11-25	Compounds, compositions, and methods
MXPA06012796A (es)	2007-05-09	Ciertas entidades quimicas, composiciones y metodos.
MY169308A (en)	2019-03-21	Treatment of tnf? related disorders
WO2004064741A3 (en)	2005-01-27	Compounds, compositions, and methods
NO20021907D0 (no)	2002-04-23	Metoder og blandinger som anvender kinazolinoner
NO20026172L (no)	2003-02-20	Fremgangsmåter og blandinger ved anvendelse av kinazolinoner
DK1305286T3 (da)	2005-03-14	Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
NO20003600D0 (no)	2000-07-13	Kaliumkanal inhibitorer
WO2003074550A3 (en)	2003-12-04	Pin1-modulating compounds and methods of use thereof
AU2003252025A1 (en)	2004-02-02	Compounds, compositions, and methods
WO2004032840A3 (en)	2004-10-14	Compounds, compositions, and methods
WO2005046588A3 (en)	2005-08-11	Compounds, compositions, and methods
WO2005042697A3 (en)	2005-09-29	Compounds, compositions and methods
WO2004032879A3 (en)	2004-07-15	Compounds, compositions, and methods
WO2004100873A3 (en)	2005-08-18	Compounds, compositions, and methods
WO2004024086A3 (en)	2004-07-22	Compounds, compositions and methods
WO2005062847A3 (en)	2006-03-30	Compounds, compositions and methods
NO20016380L (no)	2001-12-27	Fremgangsmåte for å forhindre tumorvekst
WO2005041888A3 (en)	2005-06-23	Pyrimidin-4-one compounds, compositions and methods
WO2004103282A3 (en)	2005-03-24	Compounds, compositions and methods
WO2004091547A3 (en)	2005-05-06	Compounds, compositions, and methods